Lei Xu

Dr. Lei Xu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Annals of Human Biology
Verified
Journal Article
Open access
LGLan Gao
Lan Gao
LDLisen Dong
Lisen Dong
YNYixuan Niu
Yixuan Niu
MJMeiyun Jian
Meiyun Jian
JYJunli Yang
Junli Yang
LXLei Xu
Lei Xu
The relationship between methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms and H-type hypertension susceptibility has been deeply analysed, but the conclusions are not consistent. Therefore, we carried out a meta-analysis aimed at assessing the relationship exactly. Six English databases (PubMed, Embase, EBSCO, ScienceDirect, Cochrane Library, and Web of Science) and four Chinese databases (China Biological Medicine, WanFang, China Science and Technology Journal, and China National Knowledge Infrastructure) were used for searching studies from inception to August 2023. MTHFR C677T/A1298C and MTRR A66G genetic polymorphisms were evaluated. A total of 24 papers were included in our research, including 3649 H-type hyperpietics, 2772 non-H-type hyperpietics, and 2149 healthy controls. Our analysis shows that MTHFR C677T polymorphism showed significant association with H-type hypertension in both healthy individuals and non-H-type hyperpietics (TT vs. CC: OR = 3.43, 95% CI = 2.48-4.75). Further subgroup analysis based on geography revealed that homocysteine levels in the southern Chinese population were more susceptible to MTHFR C677T polymorphism (p < 0.05). However, there was no significant association in all genetic models for the polymorphisms of MTHFR A1298C and MTRR A66G. MTHFR C677T polymorphisms are associated with H-type hypertension in non-H-type hyperpietics and healthy individuals.

13 March 2026 in Kidney Medicine
Verified
Journal Article
Open access
WHWenping Hou
Wenping Hou
PXPeitao Xie
Peitao Xie
YFYa Fu
Ya Fu
CWCen Wang
Cen Wang
KWKun Wang
Kun Wang
CSChanghai Su
Changhai Su
To evaluate the efficacy and safety of 12 phosphorus-lowering drugs for hyperphosphatemia in chronic kidney disease 3-5 stages. Systematic review and network meta-analysis of randomized controlled trials (RCTs). We searched 3 databases from inception through September 2023 for RCTs evaluating 12 phosphorus-lowering drugs. We performed frequentist random-effects network meta-analyses and present mean differences and 95% CIs. Subgroup analyses were performed between the dialysis and nondialysis patients to assess robustness, source of heterogeneity, and risk of bias using the Cochrane risk of bias assessment tool. We included 121 trials (18,376 participants) and compared 13 drugs or placebo. In terms of efficacy, except for sodium ferrous citrate, all drugs lowered the level of serum phosphorus compared with placebo. Sucroferric oxyhydroxide (PA21), nicotinic acid, and tenapanor were most likely to be ranked the best, second best, or third best. Calcium/magnesium carbonate, nicotinic acid, and colestilan posed lower risks for hypercalcemia than calcium-based phosphorus binders. All phosphorus-lowering drugs significantly affect serum intact parathyroid hormone levels compared with placebo. Colestilan, tenapanor, and PA21 posed a higher risk for gastrointestinal discomfort. In addition, iron-containing drugs showed positive effects on iron parameters. Few high-quality RCTs; unclear allocation concealment and blinding; low evidence quality reduced reliability. PA21 has the best phosphorus-lowering effect in hyperphosphatemic adults with chronic kidney disease; considering efficacy and safety, calcium carbonate shows evidence of being the most appropriate drug with or without dialysis. Registered at PROSPERO (CRD42024500243).

20 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MLMengmeng Liu
Mengmeng Liu
ZWZhe Wang
Zhe Wang
YCYongbo Chen
Yongbo Chen
YJYuqi Jia
Yuqi Jia
LXLei Xu
Lei Xu
LZLibo Zhao
Libo Zhao
Background/Objectives: Narrow therapeutic index (NTI) drugs are characterized by a small margin between effective and toxic exposure. This review aimed to summarize international definitions and regulatory frameworks for NTI drugs, compare bioequivalence requirements for generic NTI products, and evaluate the role of model-informed approaches in precision dosing and lifecycle risk management. Methods: A structured literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus, and the China National Knowledge Infrastructure from database inception to 30 June 2026. Official documents from major regulatory authorities were also reviewed. Evidence relating to NTI drug classification, bioequivalence, interchangeability, therapeutic drug monitoring, population pharmacokinetics, physiologically based pharmacokinetics, machine learning, and hybrid modeling was included. Results: Definitions, drug lists, study designs, and bioequivalence criteria varied substantially across jurisdictions. Several authorities use narrowed acceptance ranges, whereas China and the United States apply fully replicated crossover designs with reference-scaled average bioequivalence, average bioequivalence constraints, and within-subject variability comparisons for selected NTI drugs. Population pharmacokinetic and Bayesian approaches remain the most mature tools for therapeutic drug monitoring and individualized dosing. Physiologically based models support drug–drug interaction prediction, special-population extrapolation, virtual bioequivalence, and clinically relevant formulation specifications. Machine-learning and hybrid models improve exposure, dose, and toxicity-risk prediction, but most evidence remains retrospective and externally limited. Conclusions: NTI drug regulation and clinical management remain heterogeneous. Greater international harmonization, standardized model validation, prospective clinical evaluation, and integration of regulatory, formulation, and patient-level data are needed to support safer substitution and more reliable precision dosing.